From: Anti-neuron antibody syndrome: clinical features, cytokines/chemokines and predictors
In 110 ANAS patients | In 51 ANAS patients with CSF | ||||
---|---|---|---|---|---|
Outcomes | OR(95%CI) | p | Outcomes | OR(95%CI) | p |
Tumours | 10.156(1.458-70.748) | 0.0193 | Tumours | 13.859 (2.242-85.683) | 0.0047 |
Types of onset | 13.921(1.279-151.586) | 0.0306 | |||
Relapses | Per-SD increase [OR(95%CI)] | p | |||
serum TGFβ1/serum CXCL13 | 5.809 (1.349-25.002) | 0.0182 | |||
CSF BAFF | 0.038(0.001-0.988) | 0.0491 |